What is SCYX's current stock price?

SCYX (SCYNEXIS, Inc.) is currently trading at $0.73 with a market cap of $36.8M.

What sector is SCYNEXIS, Inc. in?

SCYNEXIS, Inc. (SCYX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.

InvestLog

SCYX SCYNEXIS, Inc.

Healthcare

$0.73+3.00%ClosedMarket Cap: $36.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.90

P/S

1.81

EV/EBITDA

-0.11

DCF Value

$-3.05

FCF Yield

-16.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-119.9%

Net Margin

-120.5%

ROE

-57.2%

ROA

-31.6%

ROIC

-39.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-21.3M	$—
Q4 null	$18.6M	$12.3M	$—
FY null	$20.6M	$-8.6M	$—
Q3 null	$334.0K	$-8.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2025-10-28

Trading Activity

Insider Trades

View All

Angulo Gonzalez Daviddirector, officer: Chief Executive Officer

BuyThu Apr 02

Sukenick Scottofficer: Chief Legal Officer

SellMon Feb 02

Macleod ivorofficer: Chief Financial Officer

SellMon Feb 02

Angulo Gonzalez Daviddirector, officer: Chief Executive Officer

SellMon Feb 02

Angulo Gonzalez Daviddirector, officer: Chief Executive Officer

SellTue Oct 21

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Exchange

—

Beta

1.12

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Peers

NXL